

**SUSHILA N. PATEL**  
**111, Glory, Super City Township, Iscon Temple Road, Santej,**  
**Gandhinagar- 382721.**

**April 28, 2022**

To,  
Compliance Officer,  
**Earum Pharmaceuticals Limited,**  
G1, Ground Floor, V R Complex,  
Near Sanathal Croass Road,  
SP Ring Road,  
Ahmedabad -382210.

To,  
Managing Director,  
**BSE Limited**  
Phizore Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

Dear Sir/Madam,


**Ref.: Earum Pharmaceuticals Limited**

**Sub.: Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Please find attached disclosures which are required to be made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Kindly take the same on your record and disseminate the information.

Yours faithfully,

  
**Sushilaben N. Patel (Seller)**

**Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC)	Earum Pharmaceuticals Limited		
Name(s) of the seller and Persons Acting in Concert (PAC)with the seller	Sushilaben N. Patel		
Whether the acquirer belongs to Promoter/Promoter group	Promoter Group		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited		
Details of the acquisition- / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC(**)
<b>Before the disposal under consideration, holding of :</b>			
a) Shares carrying voting rights	1539881	2.50%	2.50%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
<b>Total (a+b+c+d)</b>	<b>1539881</b>	<b>2.50%</b>	<b>2.50%</b>
<b>Details of acquisition/sale</b>			
a) Shares carrying voting rights acquired/sold	250000	0.41%	0.41%
b) VRs acquired /sold otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold			
d) Shares encumbered / invoked/released by the acquirer			
<b>Total (a+b+c+d)</b>	<b>250000</b>	<b>0.41%</b>	<b>0.41%</b>

<b>After the acquisition/sale, holding of:</b>			
a) Shares carrying voting rights	1289881	2.09%	2.09%
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
<b>e) Total (a+b+c+d)</b>	<b>1289881</b>	<b>2.09%</b>	<b>2.09%</b>
Mode of <del>acquisition</del> / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market		
Date of <del>acquisition</del> / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	April 27,2022		
Equity share capital / total voting capital of the TC before the said <del>acquisition</del> / sale	12,33,58,200		
Equity share capital/ total voting capital of the TC after the said <del>acquisition</del> / sale	12,33,58,200		
Total diluted share/voting capital of the TC after the said <del>acquisition</del> / sale	12,33,58,200		

(\* ) Total share capital/ voting capital to be taken as per the latest filing done by the Company to the Stock Exchange i.e. shareholding pattern filed by the Target Company for the quarter ended March 31,2022.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

**Signature of the ~~acquirer~~ / seller / ~~Authorised Signatory~~:**

*Sushila N. Patel*

**Sushila N. Patel**  
**Place: Ahmedabad**

**Date: April 28, 2022**